Kathleen Madden on Managing AEs From Targeted Therapies for Melanoma

Article

Kathleen M. Madden discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.

Kathleen M. Madden, MSN, FNP-BC, AOCNP®, APHN, from Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.

The entire process starts with trust and a good relationship between the patient and nurse, Madden says. Patients need to be taught that no matter how minor an issue may seem on the surface, it could develop into something more significant. On a similar note, patients don’t always understand the significance of a side effect before treatment begins.

Madden says in her workflow, she and other nurses appreciate when patients call if they have a question, but they don’t always call early enough.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.